Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Ready
Primary summary from verified readiness
- Confidence
- 67% · stale
- Computed at
- 2026-08-20T10:52:40.063881+00:00
- Claimed
- 75
- Reported
- 69
- Verified
- 60
- Gap
- +15
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-08-20
Track; not yet
- Why
- Best-in-class personalized-cancer-vaccine signal with durable 5-year Phase 2b RFS benefit, but pivotal Phase 3 confirmation and a regulatory approval are still pending; not yet a deployable/adoptable product.
- Next
- Monitor INTerpath-001 (Phase 3 adjuvant melanoma) primary readout and FDA/EMA filing timing as the maturity inflection signal
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 7
- Tier 1
- 0
- Tier 2
- 4
- Tier 3
- 3
- Supports
- 5
- Contradicts
- 2
- Context
- 0
- Latest observed
- 2026-06-01
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-07-19 Reading moved from ready to ready.